LMNX Stock News 17.81 05/13/2014 18:55:50 Luminex Cor (LMNX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Luminex Cor (LMNX) 17.81 $LMNX

Luminex Corporation Announces Group B Streptococcus (GBS), as a Launch Menu Assay for its New Sample-to-Answer System, ARIES(TM)
PR Newswire - Mon May 12, 6:30AM CDT
Luminex Corporation (NASDAQ: LMNX) today announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES(TM). The assay will complement Luminex's growing portfolio of ASR and IVD products. Previously announced items in the five assay launch menu targeted for the ARIES system include: Flu A/B and RSV, HSV 1&2, Norovirus, and Clostridium difficile (C. diff).

Global Flow Cytometry (Reagents, Instruments, Software, & Accessories) Market - Global Forecasts to 2018
M2 - Wed May 07, 11:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/38ct22/flow_cytometry) has announced the addition of the "Flow Cytometry Market by Technology, Products & Services, Application, End User - Global Forecasts to 2018" report to their offering. On the basis of products, the global flow cytometry market has been segmented into instruments, reagents and consumables, software, services, and accessories. In 2013, the reagents and consumables segment accounted for the largest share of 45%in the global market, and is also expected to grow at the highest CAGR of 11.2% from 2013 to 2018. In addition, the global market is classified into three segments based on the type of technology, namely, cell-based, bead-based, and others. The cell-based segment accounted for the largest share of 80% in the global market In the report, the global market is further segmented on the basis of type of end users, which includes commercial organizations, hospitals, academic institutions, medical schools, and clinical testing labs. In 2013, the commercial organization segment accounted for the largest share of 35% in the market. Likewise, based on the type of applications, the global market is classified into three categories, namely, research, clinical, and industrial applications. Application of flow cytometry in the research fields commands the major chunk of the market in 2013. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Industry Trends 6 Global Flow Cytometry Market, By Technology 7 Global Flow Cytometry Market, By Product 8 Flow Cytometry Market, By Application 9 Flow Cytometry Market, By End User 10 Global Flow Cytometry Market, By Geography 11 Competitive Landscape 12 Company Profiles Companies Mentioned: - Beckman Coulter, Inc. (A Subsidiary Of Danaher Corporation) - Becton, Dickinson And Company - Bio-Rad Laboratories, Inc. - Ebioscience, Inc. (A Subsidiary Of Affymetrix, Inc.) - Emd Millipore Corporation (A Division Of Merck Kgaa) - Life Technologies Corporation (A Brand Of Thermo Fisher Scientific, Inc.) - Luminex Corporation - Miltenyi Biotech - Partec Gmbh - Ttp Labtech Ltd. For more information visit http://www.researchandmarkets.com/research/38..._cytometry

Luminex Corporation Announces European Unveiling of its New Sample-to-Answer System at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
PR Newswire Europe - Sun May 04, 11:01PM CDT
-- System's Innovative Design and Ease-of-Use Will Streamline Laboratory Workflow

Positive Data, Financial Results, and Drug Development Programs - Analyst Notes on Novavax, Ironwood, XOMA, Luminex and Amicus
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novavax, Inc. (NASDAQ: NVAX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), XOMA Corporation (NASDAQ: XOMA), Luminex Corporation (NASDAQ: LMNX) and Amicus Therapeutics, Inc. (NASDAQ: FOLD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1940-100free.

Luminex Corporation To Present At UBS Global Healthcare Conference
PR Newswire - Thu May 01, 3:05PM CDT
Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the UBS Global Healthcare Conference to be held May 19-21, 2014, in New York, NY.

Global Gene Expression Market Technology, Consumables, Services & Applications Report 2014-2019
M2 - Thu May 01, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5nrjl2/gene_expression) has announced the addition of the "Global Gene Expression Market Technology, Consumables, Services & Applications Report 2014-2019" report to their offering. Gene expression analysis has emerged as a major advancement in the fields of drug discovery, diagnostics, and biomedical research. Since the completion of the Human Genome Project in 2003, numerous methods are being developed to improve the efficiency and effectiveness of gene expression profiling and sequencing. it is an important process, as it enables researchers to decipher the functions of genes. By sequencing genes, researchers can determine how diseases affect a cell. Genome-wide analysis can be used to accurately classify diseases. This has led to its increased use in various applications such as pharmacogenomics, diagnostics, toxicogenomics, and biomarkers. The global market was valued at $2.6 billion in 2013 and is expected to reach $4.3 billion by 2018, at a CAGR of 10.4%. Increasing number of cancer patients, growth in the number of funding activities, technological advancements, and increased interest in gene expression for research and discovery are the major factors driving the growth of this market. Moreover, various government bodies have extended their help in the form of investments, funds, and grants, which has further stimulated the growth of the market. Life Technologies (U.S.), QIAGEN N.V. (Netherlands), Illumina, Inc. (U.S.), Roche Diagnostics (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies (U.S.), Affymetrix, Inc. (U.S.), GE Healthcare (U.K.), Thermo Fisher Scientific (U.S.), PerkinElmer, Inc. (U.S.), Luminex Corporation (U.S.), and Oxford Gene Technology, Inc. (U.K.) are some of the prominent players in the global market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview - Increasing Number Of Cancer Patients Globally - Increase In Investments, Funds, And Grants By Government Bodies Worldwide - Technological Advancements - Small Rnas Gaining Momentum - Gene Expression Databases To Aid Cancer Research - Use Of Microarray Technology To Aid Gene Expression Studies - Use Of Sbs Technology To Aid More Detailed Cancer Studies - High Cost Of Instruments - Dearth Of Technical Expertise - Rising Opportunities In Emerging Nations - Growth In Personalized Medicine (Gene Therapy) - Sequencing Platforms - Gene Expression Application Market Analysis 4 Gene Expression Analysis Market, By Segment 5 Gene Expression Analysis Instrumentation Market, By Technology - DNA Microarrays - Real-Time Polymerase Chain Reaction (Rt-Pcr) - Next Generation Sequencing - Serial Analysis Of Gene Expression (Sage) - Northern Blotting 6 Gene Expression Analysis Consumables Market, By Product - DNA Chips - Oligonucleotides - CDNA - Reagents 7 Gene Expression Analysis Services Market, By Product - Gene Expression Profiling Services - Bioinfomatics Solutions - Data Analysis Software 8 Gene Expression Analysis Market, By Application - Diagnostics - Drug Discovery - Academic Research - Biomarkers - Others 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles - Affymetrix, Inc. - Agilent Technologies - Bio-Rad Laboratories, Inc. - Ge Healthcare (Subsidiary Of General Electric Company) - Illumina, Inc. - Life Technologies - Luminex Corporation - Oxford Gene Technology, Inc. - Perkinelmer, Inc. - Qiagen N.V. - Roche Diagnostics Corporation For more information visit http://www.researchandmarkets.com/research/5n...expression

Nasdaq stocks posting largest percentage increases
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Why Luminex (LMNX) Stock Is Up Today
at The Street - Tue Apr 29, 2:20PM CDT
Luminex (LMNX) is up after beating analysts 2014 first quarter earnings estimates.

Luminex 1Q Earnings Rise 50%, Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 1:13PM CDT
For 2014, Luminex reiterated its revenue guidance in the range of $225 to $240 million, reflecting an increase of 5 to 12% over 2013.

Luminex Corporation Reports First Quarter 2014 Results
PR Newswire - Mon Apr 28, 3:05PM CDT
Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter ended March 31, 2014. Financial and operating highlights include the following:

Downtrend Call Working As Luminex Stock Falls 12.4% (LMNX)
Comtex SmarTrend(R) - Mon Apr 28, 9:20AM CDT
SmarTrend identified a Downtrend for Luminex (NASDAQ:LMNX) on March 24th, 2014 at $18.40. In approximately 1 month, Luminex has returned 12.39% as of today's recent price of $16.12.

Luminex Corporation Announces Norovirus as a Launch Menu Assay for its New Sample-to-Answer System, ARIES(TM)
PR Newswire - Tue Apr 22, 3:05PM CDT
Luminex Corporation (NASDAQ: LMNX) today announced that norovirus will be the fourth assay in the launch menu for its new sample-to-answer system, ARIES(TM). The assay is designed to test for both GI and GII genogroups in a single, easy-to-use cassette. The previously announced items in the five assay launch menu targeted for the ARIES system also include: Flu A&B/RSV, HSV 1&2, and Clostridium difficile (C. diff). Future menu items will be announced at a later date.

Global Companion Diagnostics Market 2014-2018 with Abbott Laboratories, Agilent Technologies, bioMerieux SA, Qiagen N.V. & Roche Holding Dominating
M2 - Wed Apr 16, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3lb2g2/global_companion) has announced the addition of the "Global Companion Diagnostics Market 2014-2018" report to their offering. The Global Companion Diagnostics market will grow at a CAGR of 18.59 percent over the period 2013-2018. One of the major trends being witnessed in the market is the increase in growth strategies among vendors. Many diagnostic companies are adopting various strategies such as licensing agreements, product launches, collaborations, acquisitions, capital investment, and government support to develop companion diagnostic theranostic tests and targeted therapeutics and to strengthen their diagnostics product portfolio. Thus, many such activities are expected to boost the development of new diagnostic devices, thereby bolstering the growth of the Global Companion Diagnostics market during the forecast period. According to the report, the increased focus on cost cutting in the drug discovery and development process is one of the major drivers. The growth of genomics and proteomics has enabled the understanding of different expression stages associated with a specific disease among the human population. This has enabled many companies to develop highly specific drugs known as targeted therapeutics. It has also allowed better management of the drug development process, resulting in effective cost management. The paradigm shift in the focus to develop targeted therapeutics has enabled the development of companion diagnostic tests to monitor and administer patients with ease. Further, the report states that one of the major challenges in this market is the high cost involved in the development of companion diagnostics. The cost of developing companion diagnostics is high and adds to the overall cost of the targeted therapeutics and diagnostic tests. This report covers the present scenario and the growth prospects of the Global Companion Diagnostics market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of companion diagnostic tests and associated kits provided by the vendors. It also presents the vendor landscape and a corresponding detailed analysis of key five vendors in the Global Companion Diagnostics market. The market is highly fragmented, with the presence of many small and large vendors. It includes vendors that operate across the globe and have a substantial presence in North America and the European Union. In addition, the report discusses the major drivers that influence the growth of the Global Companion Diagnostics market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. Key Vendors - Abbott Laboratories - Agilent Technologies Inc. - bioM?rieux SA - Qiagen N.V. - Roche Holding AG Other Prominent Vendors - 20/20 Genesystems Inc. - A & G Pharmaceutical Inc. - AccuTheranostics Inc. - Alacris Theranostics GmbH - AutoGenomics Inc. - Biogenex Laboratories Inc. - Leica Biosystems GmbH - Life Technologies Inc. - Luminex Corp. - pHLOGISTIX LLC - Spartan Bioscience Inc. - TheraDiag S.A. - Theranostics Health Inc. - Ventana Medical Systems Inc. Key Market Drivers/Trends/Challenges - Increasing Focus on Reducing the Cost of Drug Discovery and Development. - High Cost Associated with the Development of Companion Diagnostics. - Increase in Growth Strategies among Vendors Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3l..._companion

Balanced View of Luminex Corporation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 5:30PM CDT
Luminex is optimistic about the life science research market and foresees continued favorable trends with respect to demand from its clinical customers.

Luminex Has Returned 9.8% Since SmarTrend Recommendation (LMNX)
Comtex SmarTrend(R) - Mon Apr 14, 5:16PM CDT
SmarTrend identified a Downtrend for Luminex (NASDAQ:LMNX) on March 24th, 2014 at $18.40. In approximately 3 weeks, Luminex has returned 9.84% as of today's recent price of $16.59.

Global High Throughput Screening (Cell Based, Ultra High Throughput Screening (uHTS), Label Free, Bioinformatics) Market 2014-2018
M2 - Fri Apr 11, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wnx4xn/high_throughput) has announced the addition of the "High Throughput Screening (HTS) Market by Technology, Applications & by End Users - Forecast to 2018" report to their offering. The global HTS market was valued at $13,736 million in 2013 and is expected to reach $19,627 million by 2018, at a CAGR of 7.4% In recent years, the high throughput screening (HTS) market has witnessed a large number of technological advancements, which has resulted in an increase in the rate of adoption of HTS in laboratories. . The HTS market is broadly classified into five segments, namely, technologies, products, applications, end users, and geography. The technology market is sub-divided into ultra high throughput screening, cell-based assays, lab-on-a chip, label-free technology, and bioinformatics. The cell-based assays segment dominated the HTS market in 2013, followed by the lab-on-a-chip segment. The HTS products market is broadly categorized into instruments, consumables/reagents, and software and services. The consumables/reagents segment dominated this market in 2013, with a market share of around 57%. The applications market is segmented into target identification, primary screening, toxicology, stem cell biology, and others. Target identification dominated the HTS applications market in 2013, followed by the primary screening market. The HTS market by end user is broadly categorized into pharmaceutical companies, biotechnology companies, academic and government institutes, contract research organizations (CROs), and others. The pharmaceuticals segment dominated the market in 2013, with a market share of around 48%. The major factors driving the growth of the HTS market are technological innovations, open innovation models adopted by pharmaceutical companies, increasing drug discovery initiatives by academic institutions, and huge capital investments in HTS technology by organizations. Moreover, the presence of a large untapped market in emerging countries and growth in outsourcing of drug discovery services especially in China and India are the various factors that are expected to provide growth opportunities for players in this market. However, the capital intensive nature of HTS and difficulties in assay development for novel target classes are the factors curbing the growth of this market. Company Profiles - Agilent Technologies, Inc. - Aurora Biomed - Axxam Spa - Beckman Coulter, Inc. (A Subsidiary Of Danaher) - Bio-Rad Laboratories - Biofocus Dpi Ltd. - Intellicyt Corporation - Luminex Corporation - Perkinelmer, Inc. - Sigma Aldrich Corporation - Tecan Group Ltd. - Thermo Fisher Scientific, Inc. Scope of the Report Technology - Cell-Based Assay - Ultra high throughput screening (uHTS)Lab-on-a-chip - Label Free Technology - Bioinformatics Product - Instruments - Consumables/Reagents - Software and Services Application - Target Identification - Primary Screening - Toxicology - Stem Cell Biology - Others End User - Pharmaceutical - Biotechnology - Academic & Government Organizations - Contract Research Organizations - Others For more information visit http://www.researchandmarkets.com/research/wn...throughput

Global Proteomics Market (Technology, Instruments, Reagents & Services) - Global Forecast to 2018
M2 - Tue Apr 08, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2hnkrt/proteomics_market) has announced the addition of the "Proteomics Market by Technology, Instruments, Reagents & Services - Global Forecast to 2018" report to their offering. The global market was valued at an estimated $10,223.3 million in 2013. The growth of this market is mainly fuelled by the increasing need for personalized medicine, growth in pharmaceutical and biotechnology research and development (R&D) expenditure, technological advancements, and availability of government and private funding for proteomics projects.The overall market is further divided into four major geographies, namely, North America, Europe, Asia, and the Rest of the World (RoW). These regions are further analyzed at the country level. This report discusses the key market drivers, restraints, and opportunities in the global proteomics market and its sub-markets. Based on reagents type, the market is segmented into protein microarray, spectroscopy, X-ray crystallography, chromatography, electrophoresis, immunoassay, and protein fractionation kits. Furthermore, the services market is sub-divided into analytical laboratory services, and data analysis and maintenance. Analytical laboratory services are further segmented into three types, namely, protein identification, protein separation, and protein sequencing. Data analysis and maintenance is further divided into bioinformatics databases and bioinformatics tools. North America accounted for the largest share of the global market in 2013, followed by Europe, Asia-Pacific, and the Rest of the World. Developed geographies like North America and Europe are likely to grow at lower CAGRs as compared to the Asian market. The growth in the Asian market is attributed to the shift of focus of the proteomics research-related industries towards Asia and the increase in both public and private funding to boost proteomic research in the region. Scope of the Report Proteomics Instrumentation Technologies - Protein Microarray - - Biochips - - Microarray instruments - Spectroscopy - - Mass spectrometry - - NMR spectrometry - - Circular dichroism (CD) spectroscopy - X-ray Crystallography - Chromatography - - HPLC Systems - - Affinity chromatography - - Ion chromatography - Supercritical Fluid Chromatography - Electrophoresis - - Gel electrophoresis - - Capillary electrophoresis - Surface Plasmon Resonance System (SPR System) - Protein Fractionation System Proteomics Reagents - Microarray - Spectroscopy - X-ray Crystallography - Chromatography - Electrophoresis - Immunoassay - Microsphere - Protein Fractionation Kits Proteomics Services - Analytical Laboratory Services - Protein Identification - Protein Separation - Protein Sequencing - Data Analysis and Maintenance - Bioinformatics Databases - Bioinformatics Tools - Global Proteomics Market, by Application - Drug Discovery - Diagnosis Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - Proteomics Instrumentation Technology - Proteomics Reagents Market - Proteomics Services Market - Proteomics Applications Market - Geographic Analysis - Competitive Landscape - Company Profiles - Thermo Fisher Scientific Inc. - Agilent Technologies, Inc. - Bio-Rad Laboratories, Inc. - Luminex Corporation - Danaher Corporation - Ge Healthcare - Waters Corporation - Affymetrix Inc. - Perkinelmer, Inc. - Sigma-Aldrich Corp Visit http://www.researchandmarkets.com/research/2h...ics_market

Global Multiplexed Diagnostics Market (Technologies & Applications) 2013 - 2019
M2 - Tue Apr 08, 2:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m73r7s/multiplexed) has announced the addition of the "Multiplexed Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report covers the market analysis of the multiplexed diagnostics technologies namely, very high, high, medium, low density multiplexed assays & next-generation sequencing. This report contains qualitative information about oligonucleotide arrays, phage display, bacterial artificial chromosome arrays, protein arrays, bead-based arrays, antibody arrays, reverse arrays, mass spectrometry, quantitative PCR bead-based and microplate assays and next-generation sequencing. The market is also segmented on the basis of several application areas of multiplexed diagnostics, namely, infectious disease diagnosis, oncology, autoimmune diseases, cardiac conditions, allergies and others (Alzheimer's disease, diabetes, kidney toxicity and HIV). The global multiplexed diagnostics market has phenomenally increased the volume and quality of diagnostic procedures by reducing the turnaround time and analyzing multiple analytes in a single cycle and thereby resulting in rapid adoption of such techniques. The stake holders in this market include market players who provide multiplexed diagnostic assay kits, reagents, solutions and systems. The qualitative details of the market dynamics of the multiplexed diagnostics market such as drivers, restraints and opportunities that influence the current nature and future status of this field are covered under the market overview section of this report. Impact factors such as market attractiveness analysis and Porter's five forces analysis have also been provided in the market overview section of the report in order to give a thorough analysis of the overall competitive scenario in the global multiplexed diagnostics market. The market size and forecast in terms of USD million has been provided in the report for the period 2011 to 2019. This report also includes the overall market growth rate (Compounded Annual Growth Rate) of technologies, applications and geographic market for the period 2013 to 2019, considering 2012 as the base year. The global multiplexed diagnostics market is segmented as follows: Technology - Very high density multiplexed assays - - Oligonucleotide Arrays - - Phage Display - High Density Multiplexed Assays - - Bacterial Artificial Chromosome Arrays - - Protein Arrays - Medium Density Multiplexed Assays - - Bead-based Arrays - - Antibody Arrays - - Reverse Arrays - - Mass Spectroscopy - Low Density Multiplexed Arrays - - Quantitative PCR Bead-based Assays - - Microplate Assays - Next-Generation Sequencing Application - Infectious Disease Diagnosis - Oncology - Autoimmune diseases - Cardiac - Allergies - Others Key Topics Covered: - Introduction - Executive Summary - Multiplexed Diagnostics Market Overview - Global Multiplex Assays Market, by Technology - Global Multiplex Diagnostics Market, By Application - Global Multiplexed Diagnostics Market, by Geography - Recommendations - Company Profiles - Affymetrix, Inc. - Agilent Technologies, Inc. - bioMerieux, Inc. - Bio-Rad Laboratories, Inc. - Illumina, Inc. - F. Hoffman-La Roche, Ltd. - Gen-Probe, Inc. - Life Technologies Corporation - Luminex Corporation - Seegene, Inc. Visit http://www.researchandmarkets.com/research/m7...ultiplexed
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 38

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
Epsium's Inventory Pile Looms Over Weak First Half

Updated Category News Views 73

A warehouse full of bottles is not a balance-sheet fortress when buyers are backing away. Epsium Enterprise’s first-half 2026 report is a rough read: revenue collapsed 51.8% to $1.47 million, gross profit fell to $175,353, and cash slid to $612,761 at June 30. This is not a subtle slowdown. Macau’s premium Chinese-liquor market has been weak on both demand and...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 76

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 79

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 146

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 49

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 165

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 171

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 138

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading

Top 5 Most Recently Viewed Articles

Artisan Partners Asset Management's Q2 Performance and Highlights

Updated Category News Views 124

Artisan Partners Asset Management Inc. Reports Strong Q2 Performance Artisan Partners Asset Management Inc. (NYSE: APAM) recently showcased its financial success for the quarter ending June 30, 2025. The Company, renowned for its investment strategies, declared a quarterly dividend as part of its results presentation. This reflects Artisan's commitment to providing value...

Continue Reading
LVMH Reports Recent Share Transactions and Market Activity

Updated Category News Views 240

Understanding LVMH's Share Transactions Recently, LVMH Moët Hennessy Louis Vuitton disclosed share transactions conducted between exciting dates. This information was provided to the regulatory body, ensuring transparency for investors and industry stakeholders alike. As one of the leading companies in the luxury goods sector, LVMH’s transactions are always...

Continue Reading
Dynavax Technologies to Share Insights at Healthcare Conference

Updated Category News Views 160

Dynavax's Upcoming Participation in Healthcare Conference Dynavax Technologies Corporation (Nasdaq: DVAX), a prominent player in the biopharmaceutical landscape, is set to take part in a pivotal fireside chat at the 8th Annual Evercore Healthcare Conference. This insightful event will take place on an upcoming Tuesday at 2:10 p.m. ET. Investors and healthcare stakeholders...

Continue Reading
Growing Demand for 3D Surveillance Cameras by 2030

Updated Category News Views 301

The Growing Market for 3D Surveillance Cameras The global 3D surveillance camera market is on the brink of substantial growth, with forecasts indicating it could reach an impressive $7.92 billion by 2030. This surge is primarily fueled by increased investments in defense and public safety initiatives around the world. A key factor in this trend is the rising use of 3D...

Continue Reading
LVMH Stock Upgrade by BofA Signals Strong Growth Ahead

Updated Category News Views 317

LVMH Receives Positive Rating Upgrade from Bank of America Recently, Bank of America made headlines by upgrading LVMH shares to a Buy rating, moving it from a previous Neutral stance. This upgrade places the renowned luxury goods giant on its prestigious Europe 1 list of preferred investment ideas. Revised Price Targets Indicate Strong Potential The ratings agency has...

Continue Reading